title: New drug approvals in acute myeloid leukemia: what's the best end point?
authors.affiliation: Clinical Research Division and Division of Hematology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.affiliation: Public Health Sciences Division's Biostatistics and Biomathematics Group, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Othus
authors.affiliation: Clinical Research Division and Division of Medical Oncology, University of Washington, Seattle, WA, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Lee
authors.affiliation: Clinical Research Division and Division of Medical Oncology, University of Washington, Seattle, WA, USA.
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.affiliation: Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK.
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
mesh_terms: D054316:Biomarkers, Pharmacological / Q000032:analysis*; D016026:Bone Marrow Transplantation; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual; D011379:Prognosis; D011788:Quality of Life; D012074:Remission Induction; D016019:Survival Analysis; D014481:United States
chemical_list: C581634:BCR-ABL1 fusion protein, human; D054316:Biomarkers, Pharmacological; D015507:Drugs, Investigational; D016044:Fusion Proteins, bcr-abl